November 30, 2020
A U.S. District Court judge in Delaware on Monday shot down Coherus BioSciences Inc.'s bid to shift legal fees to Amgen Inc. in its failed patent infringement suit against Coherus over a blockbuster anti-infection drug.
June 09, 2017
Coherus Biosciences Inc. has told a Delaware federal court that its biosimilar application doesn’t infringe an Amgen Inc. patent covering anti-infection drug Neulasta and that Amgen’s infringement suit should be thrown out.
May 11, 2017
Amgen Inc. has sued biosimilar maker Coherus Biosciences Inc. in Delaware federal court for allegedly infringing a patent covering anti-infection medicine Neulasta, marking its latest court fight to protect the blockbuster biologic.